TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published in JAMA Network Open found similar dementia rates among adults with overactive bladder who started anticholinergic drugs or beta-3 agonists. The observational comparison does not show that either class carries no risk, and researchers say the findings need replication before clinical guidance changes.
A study of 830,393 adults with overactive bladder found similar rates of dementia among patients newly treated with anticholinergic medications and those treated with beta-3 agonists, challenging the assumption that the newer drug class carries a lower long-term dementia risk. The research, published November 6 in JAMA Network Open, does not establish that either type of medication is risk-free.
Researchers at the University Hospitals Cleveland Medical Center Urology Institute used Epic Cosmos, a national electronic health record database, to examine adults aged 40 to 90 who began treatment for overactive bladder between 2012 and 2025. The analysis compared dementia incidence between people starting anticholinergics and those starting beta-3 agonists, as well as across individual medications. The report says dementia rates were similar across the groups.
Anticholinergics are a longstanding, commonly prescribed medication option for overactive bladder. Beta-3 agonists are a newer class that has been presumed to be safer for the brain. The study’s finding is a comparison between these treatment groups: it does not compare medication users with people who received no drug treatment, and so cannot determine whether either class changes dementia risk relative to no medication.
Lead author David Sheyn, a urogynecologist at the institute, said short-term cognitive and memory side effects associated with anticholinergics can occur, though not in most people. He said those symptoms resolve after stopping the medication. That statement is attributed to the researcher; individual effects and treatment choices should be discussed with a qualified health professional.
What the Comparison Means for Patients
The results may ease concern for some people who need treatment for bladder symptoms, since concerns about dementia have been linked to anticholinergic use in earlier observational research. Sheyn said that worry can make patients reluctant to use medication that might help them. The new study, however, does not prove that anticholinergics cannot contribute to dementia or that a particular drug is suitable for every patient.
The distinction matters because the study compares two groups who were both treated for overactive bladder. Similar dementia rates between them do not answer whether either group had a different risk than people who were not treated, nor do they settle the wider question of medication effects over longer periods. The findings may inform discussion, but the report says they require replication before clinical guidelines change; beta-3 agonists remain considered the better choice whenever possible.
Products Worth Considering
Husqvarna 122C 22-cc 2-Cycle Gas String Trimmer, 17-Inch Curved Shaft
Takywep 6 x 9 ft Walk-In Greenhouse with Polycarbonate Panels
Greenworks 80V 21-Inch Self-Propelled Lawn Mower with 4.0Ah Battery and Charger
As an affiliate, we earn on qualifying purchases.
Why Bladder Drugs Drew Scrutiny
Overactive bladder can be treated with several approaches, including medication. Anticholinergic drugs have been a foundational second-line pharmacological treatment, while beta-3 agonists have been regarded as a potentially lower-risk alternative for the brain. Several observational studies have linked anticholinergic medication use with dementia, prompting concern among patients and clinicians.
Sheyn said he pursued the study partly because processes associated with dementia may begin decades before symptoms appear, while many earlier studies of bladder medicines followed patients for five years or less. The new analysis covers a longer span of treatment starts, but its observational design still cannot establish cause and effect. The authors’ paper, “Drug therapies and incidence of dementia among adults with overactive bladder,” was published in JAMA Network Open in 2026 (DOI: 10.1001/jamanetworkopen.2026.42026).
““This is potentially good news.””
— David Sheyn, lead author and urogynecologist at University Hospitals Cleveland Medical Center Urology Institute
Limits of the Dementia Findings
The analysis is observational and compares patients taking two drug classes. Because it did not include a group of people with overactive bladder who took no medication, it cannot show that either treatment carries no dementia risk. Similar rates between the two groups also cannot establish that the drugs have identical effects in every patient or at every duration of use.
The study does not prove that overactive bladder is an early sign of dementia. Sheyn said the pattern is consistent with that possibility, since the condition and neurological processes related to urinary incontinence may overlap with early neurodegenerative changes. Whether that relationship can help identify dementia earlier remains unconfirmed. The supplied report also does not provide numerical dementia rates, effect estimates, or details that would allow readers to assess the size of any difference.
Replication Before Guidance Changes
Researchers say the results need to be reproduced before clinical guidelines are reconsidered. Further research would need to clarify how dementia risk compares with no medication use, how results vary by drug and treatment duration, and whether bladder symptoms can reliably serve as an early marker of neurological disease. Until more evidence is available, people considering or taking these medicines should discuss benefits, side effects and alternatives with a qualified health professional rather than changing treatment based on this study alone.
Key Questions
Did the study find that overactive bladder drugs do not cause dementia?
No. It found similar dementia rates among patients starting anticholinergics and beta-3 agonists. Since it did not include an untreated comparison group and was observational, it cannot establish that either class has no risk or prove cause and effect.
Which medications did the study compare?
The study compared anticholinergic medications, a longstanding treatment option for overactive bladder, with beta-3 agonists, a newer class previously presumed to be safer for the brain. The supplied report does not list individual medications or their separate results.
Does overactive bladder mean someone may have dementia?
The study does not establish that. Its lead author said the findings fit a possible explanation in which overactive bladder may sometimes relate to early neurological changes, but this remains a hypothesis rather than a proven screening signal.
Should patients change their medication because of this study?
The findings do not establish a new treatment recommendation. The lead author said replication is needed before guidelines change, and the report says beta-3 agonists remain considered the better choice whenever possible. Discuss individual treatment decisions with a qualified health professional.
Source: news-medical.net
